Autoimmune hepatitis study for people in China
Part of Digestive system, Immune system & allergy clinical trials.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 14 or older
- You have a probable or definite diagnosis of autoimmune hepatitis
- At your initial autoimmune hepatitis diagnosis, you have test results for liver enzymes, bilirubin, alkaline phosphatase, immunoglobulin G, and platelet count
- You can agree to participate (informed consent)
- You do not have certain other liver/immune conditions such as primary biliary sclerosis or primary sclerosing cholangitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at specific immune cells (T cells) in the blood of people with autoimmune hepatitis (AIH) to better understand the disease. If you have untreated AIH and meet certain criteria, you may be able to participate.
This study is building a database and collection of samples from people with autoimmune hepatitis in Italy. It aims to learn more about the disease and improve care.
This study looks at people with autoimmune hepatitis (an immune system condition that attacks the liver). It aims to learn more about the disease by following patients who live in Switzerland.
This study examines the molecular profile of autoimmune hepatitis (a liver condition where the immune system attacks liver cells) using lipid analysis. Researchers hope to better understand the disease and potentially improve diagnosis and treatment in the future.
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
This study looks at factors that help predict how well people with autoimmune hepatitis respond to treatment. It is for patients who are newly diagnosed or have not had treatment for at least 3 months, and who have had a liver biopsy to confirm the diagnosis.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.